Harvard Bioscience, Inc.
HBIO
$0.3769
-$0.013-3.33%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -12.78% | -13.38% | -19.69% | -18.23% | -0.96% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -12.78% | -13.38% | -19.69% | -18.23% | -0.96% |
| Cost of Revenue | -8.74% | -13.45% | -18.26% | -16.24% | 3.46% |
| Gross Profit | -15.57% | -13.32% | -20.72% | -19.48% | -3.81% |
| SG&A Expenses | -10.82% | -8.49% | -3.90% | -3.61% | -0.73% |
| Depreciation & Amortization | -9.37% | -1.98% | -4.18% | -3.96% | -14.91% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.64% | -10.01% | -11.42% | -5.08% | 1.34% |
| Operating Income | -48.02% | -81.67% | -310.18% | -230.30% | -41.79% |
| Income Before Tax | 153.49% | -699.11% | -56.34% | -471.50% | -23.65% |
| Income Tax Expenses | -20.00% | -54.06% | 68.43% | -64.10% | -7.62% |
| Earnings from Continuing Operations | 100.99% | -287.57% | -198.67% | -854.66% | -9.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 100.99% | -287.57% | -198.67% | -854.66% | -9.12% |
| EBIT | -48.02% | -81.67% | -310.18% | -230.30% | -41.79% |
| EBITDA | -16.58% | -85.82% | -94.91% | -114.35% | -23.52% |
| EPS Basic | 100.94% | -279.66% | -191.34% | -831.08% | -7.58% |
| Normalized Basic EPS | 644.68% | -653.66% | -33.87% | -638.33% | -78.92% |
| EPS Diluted | 100.94% | -267.00% | -203.03% | -1,200.00% | -7.58% |
| Normalized Diluted EPS | 629.79% | -653.66% | -33.87% | -647.46% | -78.92% |
| Average Basic Shares Outstanding | 2.22% | 2.17% | 2.67% | 3.05% | 1.44% |
| Average Diluted Shares Outstanding | 4.08% | 2.17% | 2.67% | 1.45% | 1.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |